Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV[® ]in Europe
· The agreement covers 29 countries in Europe · Orexo will receive double-digit royalties on future net sales · First launches are expected in H2, 2021 Uppsala, Sweden – December 7, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialisation of ZUBSOLV[® ]((buprenorphine (as hydrochloride) and naloxone (as hydrochloride dihydrate)) sublingual tablet. Licensed in Europe, ZUBSOLV[®][ ]is indicated for adults and adolescents over 15 years of age for substitution treatment for opioid drug